• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    5/31/24 4:23:52 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    SC 13G/A 1 d811299dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Turnstone Biologics Corp.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    90042W100

    (CUSIP Number)

    May 13, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 90042W100

    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Timothy J. Langer

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     993,607 (1)

       6.  

     SHARED VOTING POWER

     

     0

       7.  

     SOLE DISPOSITIVE POWER

     

     993,607 (1)

       8.  

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     993,607 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of (i) 885,632 shares of Common Stock (as defined in Item 2(d) below) held of record by the Reporting Person (as defined in Item 2(a) below) and (ii) 107,975 shares of Common Stock underlying stock options granted to the Reporting Person, which are exercisable within 60 days of the date hereof.

    (2)

    Based on 23,128,454 shares of Common Stock outstanding as of May 9, 2024, as reported by the Issuer (as defined in Item 1(a) below) in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on May 13, 2024 (the “Form 10-Q”), plus 107,975 shares of Common Stock underlying stock options granted to the Reporting Person, which are exercisable within 60 days of the date hereof.


    CUSIP No. 90042W100

    13G

    Explanatory Note:

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13G initially filed with the Securities and Exchange Commission (the “Commission”) on March 18, 2024 (the “Original Schedule 13G”) and is being filed by the Reporting Person. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for the Reporting Person and the corresponding footnotes.

    (b) Percent of class:

    See Row 11 of the cover page for the Reporting Person and the corresponding footnotes.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for the Reporting Person and the corresponding footnotes.

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for the Reporting Person and the corresponding footnotes.

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for the Reporting Person and the corresponding footnotes.

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for the Reporting Person and the corresponding footnotes.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following: ☒


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: May 31, 2024

     

    /s/ Timothy J. Langer
    Timothy J. Langer
    Get the next $TSBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

      SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

      5/8/25 6:00:49 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Announces Plans to Explore Strategic Alternatives

      SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. The Company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program. As a result, Turnstone's management and its Board of Directors have initiated a process to explore and review strategic alternatives focused on maximizing shareholder value. "Manufacturing for our Selected TIL therapy requires continued investment in process improvements. Due to these capit

      2/4/25 9:00:00 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Turnstone Biologics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

      2/5/25 8:04:09 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

      11/15/24 8:23:44 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Buy to Neutral

      10/14/24 7:44:47 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gould Robert J

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:14 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gupta Rishi

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:12 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rajangam Kanya

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:15 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Turnstone Biologics Corp.

      SCHEDULE 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/12/25 10:43:30 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Turnstone Biologics Corp.

      10-K - Turnstone Biologics Corp. (0001764974) (Filer)

      3/28/25 9:08:30 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Turnstone Biologics Corp. (0001764974) (Filer)

      3/28/25 9:05:31 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

      SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

      5/13/24 5:01:26 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

      Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

      3/21/24 5:06:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Financials

    Live finance-specific insights

    See more
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/31/24 4:23:52 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      4/29/24 8:22:22 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Turnstone Biologics Corp.

      SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

      3/18/24 9:13:28 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care